Tangent90 Appoints Gemma Cholerton As Marketing Director

Tangent90 Appoints Gemma Cholerton As Marketing Director

London, United Kingdom – 3rd August 2021: Tangent90 Ltd, a leading technology company developing innovative solutions that enable pharma to overcome the challenges of sharing scientific digital content with healthcare professionals (HCPs), welcome the appointment of Gemma Cholerton as Marketing Director. 

Gemma joins from global pharmaceutical regulatory solutions provider, PharmaLex, where she held a senior marketing role, leading the marketing strategy for online and digital, brand implementation and PR. In moving to Tangent90, Gemma saw an opportunity to help the company formalise its marketing activities and support its ambitious growth plans.  

“It is an exciting opportunity to join a company that is seeing significant growth, despite the challenges of the last 18 months”, explained Gemma. “Tangent90 are ahead of the curve when it comes to digital engagement through copyright scientific content and with the momentum shifting in pharma to drive the adoption of digital solutions, there’s a real opportunity to showcase what we can do”, she added. 

“As a growing company, we recognised the need to add structure to our marketing efforts”, explained Jan van den Burg, CEO at Tangent90. “Gemma’s experience is a clear advantage and will enable us to optimise the opportunity to support pharma in taking their digital communications to the next level”, he added.  

>> Download Full Article

Related news

Tangent90

Seeing the Value of Scientific Content

In Pharmaceutical Commerce magazine, Tangent90 CEO Jan van den Burg discusses the value that HCPs place on scientific content and highlights the opportunity that pharma should be taking now.

Content

Need to scale up fast? Ready-made content can help

Veeva recently published an eBook which discusses the best practice approach for supporting emerging pharma to launch and scale content faster. It focuses on how digital communications have allowed field teams to spend more quality time with HCPs. What can pharma’s brand teams do to support the increase needed?

Using next best action to inform your engagement strategy

We have been inundated with discussions about big data. Information that can help inform decision making is an output of nearly every phase in life sciences. The industry, with the increased use of digital channels, has been able to collect more data but is this being used to optimise their HCP engagement strategies?

Scroll to Top

Book A Demo

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.